Stereological Evaluation of the Brains in Patients with Parkinson’s disease Compared to Controls

1. Halliday GM, McCann H. The progression of pathology in Parkinson’s disease. Annals of the New York Academy of Sciences. 2010;1184(1):188-95. DOI: 10.1111/j.1749-6632.2009.05118.x10.1111/j.1749-6632.2009.05118.xSearch in Google Scholar

2. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889-909. DOI: 10.1016/S0896-6273(03)00568-310.1016/S0896-6273(03)00568-3Search in Google Scholar

3. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson’s disease are predominantly associated with serotonin and dopamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(6):1104-14. DOI: 10.1016/j.pnpbp.2010.06.00410.1016/j.pnpbp.2010.06.004Search in Google Scholar

4. Mounsey RB, Teismann P. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection. Parkinson’s Disease. 2010;2011.10.4061/2011/617472Search in Google Scholar

5. Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Movement disorders. 2006;21(9):1384-95. DOI: 10.1002/mds.2099310.1002/mds.20993Search in Google Scholar

6. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. The Lancet Neurology. 2006;5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-910.1016/S1474-4422(06)70471-9Search in Google Scholar

7. Lolaty HA, Tirgari A, Fard JH. Emotional intelligence and related factors in medical sciences students of an Iranian university. Iranian journal of nursing and midwifery research. 2014;19(2):203.Search in Google Scholar

8. Fereshtehnejad S-M, Shafieesabet M, Rahmani A, Delbari A, Lökk J. Medium-to-high prevalence of screening- detected parkinsonism in the urban area of Tehran, Iran: data from a community-based door-to-door study. Neuropsychiatric disease and treatment. 2015;11:321. DOI: 10.2147/NDT.S7739110.2147/NDT.S77391Search in Google Scholar

9. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. The Lancet Neurology. 2006;5(1):75-86. DOI: 10.1016/S1474-4422(05)70285-410.1016/S1474-4422(05)70285-4Search in Google Scholar

10. Ciumas C, Montavont A, Ryvlin P. Magnetic resonance imaging in clinical trials. Current opinion in neurology. 2008;21(4):431-6. DOI: 10.1097/WCO.0b013e-3283056a3cSearch in Google Scholar

11. Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases. Neurotherapeutics. 2009;6(1):128-40. DOI: 10.1016/j.nurt.2008.10.03310.1016/j.nurt.2008.10.033508426119110204Search in Google Scholar

12. Casteleyn C, Prims S, Van Cruchten S, Van Ginneken C. Stereology: from astronomy to veterinary oncology. Veterinary journal (London, England: 1997). 2014;202(1):3-4. DOI: 10.1016/j.tvjl.2014.06.00110.1016/j.tvjl.2014.06.00124973003Search in Google Scholar

13. Qualter P, Gardner KJ, Pope DJ, Hutchinson JM, Whiteley HE. Ability emotional intelligence, trait emotional intelligence, and academic success in British secondary schools: A 5year longitudinal study. Learning and Individual Differences. 2012;22(1):83-91. DOI: 10.1016/j.lindif.2011.11.00710.1016/j.lindif.2011.11.007Search in Google Scholar

14. Brannick MT, Wahi MM, Goldin SB. Psychometrics of mayer-salovey-caruso emotional intelligence test (MSCEIT) scores 1. Psychological reports. 2011;109(1):327-37. DOI: 10.2466/03.04.PR0.109.4.327-33710.2466/03.04.PR0.109.4.327-33722049672Search in Google Scholar

15. Duygulu S, Hicdurmaz D, Akyar I. Nursing students’ leadership and emotional intelligence in Turkey. Jour nal of Nursing Education. 2011;50(5):281-5. DOI: 10.3928/01484834-20110130-0710.3928/01484834-20110130-0721323258Search in Google Scholar

16. Geng D-y, Li Y-X, Zee C-S. Magnetic resonance imaging- based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery. 2006;58(2):256-62. DOI: 10.1227/01.NEU.0000194845.19462.7B10.1227/01.NEU.0000194845.19462.7B16462479Search in Google Scholar

17. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss W-D. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(5):517-23. DOI: 10.1136/jnnp.73.5.51710.1136/jnnp.73.5.517173813112397143Search in Google Scholar

18. Gocmen-Mas N, Pelin C, Canan S, Yazici AC, Zagyapan R, Senan S, et al. Stereological evaluation of volumetric asymmetry in healthy human cerebellum. Surgical and radiologic anatomy. 2009;31(3):177-81. DOI: 10.1007/s00276-008-0424-410.1007/s00276-008-0424-418941706Search in Google Scholar

19. Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M, Rigi-Ladiz MA. Quantitative analysis of interdental Gingiva in patients with chronic periodontitis and transforming growth factor-β1 29C/T gene polymorphisms. Journal of periodontology. 2014;85(2):281-9. DOI: 10.1902/jop.2013.13008710.1902/jop.2013.13008723688102Search in Google Scholar

20. Heidari Z, Mahmoudzadeh-Sagheb H, Kohan F. A quantitative and qualitative study of rat testis following administration of methadone and buprenorphine. International Journal of High Risk Behaviors and Addiction. 2012;1(1):14-7. DOI: 10.5812/ijhrba.411910.5812/ijhrba.4119Search in Google Scholar

21. Lee CS, Schulzer M, de la Fuente-Fernández R, Mak E, Kuramoto L, Sossi V, et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Archives of neurology. 2004;61(12):1920-5. DOI: 10.1001/archneur.61.12.192010.1001/archneur.61.12.192015596613Search in Google Scholar

22. Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, et al. Asymmetrical lateral ventricular enlargement in Parkinson’s disease. European journal of neurology. 2009;16(4):475-81. DOI: 10.1111/j.1468-1331.2008.02430.x10.1111/j.1468-1331.2008.02430.x290827319187264Search in Google Scholar

23. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magneticresonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(3):254-9. DOI: 10.1136/jnnp.2006.09384910.1136/jnnp.2006.093849211763317028119Search in Google Scholar

24. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch J, Evans A, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64(2):224-9. DOI: 10.1212/01.WNL.0000149510.41793.5010.1212/01.WNL.0000149510.41793.5015668417Search in Google Scholar

25. Fahn S, Group PS. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? Journal of neurology. 2005;252(4):iv37-iv42. DOI: 10.1007/s00415-005-4008-510.1007/s00415-005-4008-516222436Search in Google Scholar

26. Douaud G, Gaura V, Ribeiro M-J, Lethimonnier F, Maroy R, Verny C, et al. Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage. 2006;32(4):1562-75. DOI: 10.1016/j.neuroimage.2006.05.05710.1016/j.neuroimage.2006.05.05716875847Search in Google Scholar

27. Mamah D, Wang L, Barch D, de Erausquin GA, Gado M, Csernansky JG. Structural analysis of the basal ganglia in schizophrenia. Schizophrenia research. 2007;89(1):59-71. DOI: 10.1016/j.schres.2006.08.03110.1016/j.schres.2006.08.031183981717071057Search in Google Scholar

28. Summerfield C, Junqué C, Tolosa E, Salgado-Pineda P, Gómez-Ansón B, Martí MJ, et al. Structural brain changes in Parkinson disease with dementia: a voxel- based morphometry study. Archives of Neurology. 2005;62(2):281-5. DOI: 10.1001/archneur.62.2.28110.1001/archneur.62.2.28115710857Search in Google Scholar

29. Cordato N, Duggins A, Halliday G, Morris J, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005;128(6):1259-66. DOI: 10.1093/brain/awh50810.1093/brain/awh50815843423Search in Google Scholar

30. Menke RA, Szewczyk‐Krolikowski K, Jbabdi S, Jenkinson M, Talbot K, Mackay CE, et al. Comprehensive morphometry of subcortical grey matter structures in early‐stage Parkinson’s disease. Human brain mapping. 2014;35(4):1681-90. DOI: 10.1002/hbm.2228210.1002/hbm.22282686897023861334Search in Google Scholar

31. Sterling NW, Du G, Lewis MM, Dimaio C, Kong L, Eslinger PJ, et al. Striatal shape in Parkinson’s disease. Neurobiology of aging. 2013;34(11):2510-6. DOI: 10.1016/j.neurobiolaging.2013.05.01710.1016/j.neurobiolaging.2013.05.017374268623820588Search in Google Scholar

32. Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al. MR imaging index for differentiation of progressive supranuclear palsy from parkinson disease and the parkinson variant of multiple system atrophy 1. Radiology. 2008;246(1):214-21. DOI: 10.1148/radiol.245306170310.1148/radiol.245306170317991785Search in Google Scholar

33. Acharya HJ, Bouchard TP, Emery DJ, Camicioli RM. Axial signs and magnetic resonance imaging correlates in Parkinson’s disease. The Canadian Journal of Neurological Sciences. 2007;34(01):56-61. DOI: 10.1017/S031716710000579510.1017/S0317167100005795Search in Google Scholar

34. Hu M, White S, Chaudhuri KR, Morris R, Bydder G, Brooks D. Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. Journal of neural transmission. 2001;108(5):571-80. DOI: 10.1007/s00702017005710.1007/s00702017005711459077Search in Google Scholar

35. Gama RL, Távora DF, Bomfim RC, Silva CE, Bruin VMd, Bruin PFd. Morphometry MRI in the differential diagnosis of parkinsonian syndromes. Arquivos de neuro- psiquiatria. 2010;68(3):333-8. DOI: 10.1590/S0004-282X201000030000110.1590/S0004-282X2010000300001Search in Google Scholar

36. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations. Movement disorders. 2006;21(7):989-96. DOI: 10.1002/mds.2087710.1002/mds.2087716602104Search in Google Scholar

37. Ertekin T, Acer N, İçer S, Vurdem ÜE, Çınar Ş, Özçelik Ö. Volume estimation of the subcortical structures in Parkinson’s disease using magnetic resonance imaging: A methodological study. Neurology Asia. 2015;20(2):143-53.Search in Google Scholar

38. Korbo L, Amrein I, Lipp HP, Wolfer D, Regeur L, Oster S, et al. No evidence for loss of hippocampal neurons in non‐Alzheimer dementia patients. Acta neurologica scandinavica. 2004;109(2):132-9. DOI: 10.1034/j.1600-0404.2003.00182.x10.1034/j.1600-0404.2003.00182.x14705976Search in Google Scholar

39. Joelving F, Billeskov R, Christensen J, West M, Pakkenberg B. Hippocampal neuron and glial cell numbers in Parkinson’s disease-a stereological study. Hippocampus. 2006;16(10):826-33. DOI: 10.1002/hipo.2021210.1002/hipo.2021216941622Search in Google Scholar

40. Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, Lafontaine A-L, et al. Regional brain stem atrophy in idiopathic Parkinson’s disease detected by anatomical MRI. PloS one. 2009;4(12):e8247. DOI: 10.1371/journal.pone.000824710.1371/journal.pone.0008247278429320011063Search in Google Scholar

41. Toulouse A, Sullivan AM. Progress in Parkinson’s disease-where do we stand? Progress in neurobiology. 2008;85(4):376-92. DOI: 10.1016/j.pneurobio.2008.05.00310.1016/j.pneurobio.2008.05.00318582530Search in Google Scholar